Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill could shield kids from TB

NCT ID NCT07124559

Not yet recruiting Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a 28-day daily combination of two drugs, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13. About 144 children, some with HIV and some without, will join to find the right dose and check for side effects. The goal is to see if this short daily treatment is safe and works for kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rifapentine and isoniazid (daily for 28 days)
What this could lead to
If successful, this could provide a safe and effective daily TB prevention regimen for children, including those with HIV.
What could go wrong
This is an early phase trial with only 144 children, so the dose and safety are still being determined. Side effects or lack of effectiveness may limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Locations

  • Baylor-Uganda (Site ID: 31798)

    Kampala, Uganda

  • Chiangrai Prachanukroh Hospital (Site ID: 5116)

    Chiang Rai, 57000, Thailand

  • Gaborone (Site ID: 12701)

    Gaborone, Botswana

  • Harare Family Care (Site ID: 31890)

    Belgravia, Harare, Zimbabwe

  • Kenya Medical Research Institute, Walter Reed Project Clinical Research Center (Site ID: 5121)

    Kericho, 20200, Kenya

  • Les Centres GHESKIO (Site ID: 30022)

    Port-au-Prince, HT-6110, Haiti

  • MU-JHU Care Limited (Site ID: 5126)

    Kampala, Uganda

  • Molepolole (Site ID: 12702)

    Gaborone, Botswana

  • Seke North (Site ID: 30306)

    Belgravia, Harare, Zimbabwe

  • Siriraj Hospital, Mahidol University (Site ID: 5115)

    Bangkok, Bangkoknoi, 10700, Thailand

  • St Mary's (Site ID: 30303)

    Chitungwiza, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.